Share on StockTwits

Jefferies Group boosted their target price on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from $14.00 to $15.00 in a research note issued on Wednesday. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price suggests a potential upside of 47.06% from the stock’s previous close.

A number of other analysts have also recently weighed in on AMPH. Analysts at BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $17.00 to $18.00 in a research note on Wednesday, August 6th. Separately, analysts at Needham & Company LLC initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $17.00 price target on the stock. Finally, analysts at Piper Jaffray initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Monday, July 21st. They set an “overweight” rating and a $16.00 price target on the stock.

Amphastar Pharmaceuticals (NASDAQ:AMPH) traded down 1.79% on Wednesday, hitting $10.0176. 67,523 shares of the company’s stock traded hands. Amphastar Pharmaceuticals has a one year low of $6.67 and a one year high of $11.07. The stock has a 50-day moving average of $9.34 and a 200-day moving average of $9.34. The company has a market cap of $434.8 million and a P/E ratio of 50.25.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings data on Tuesday, August 12th. The company reported $0.02 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.13. Analysts expect that Amphastar Pharmaceuticals will post $-0.33 EPS for the current fiscal year.

Amphastar Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.